MDoutlook celebrates its 8th consecutive year of syndicated research gauging the clinical impact of new data presented at ASCO 2015. Building on over 30 analyses since 2008, MDoutlook today releases the first analysis in a new series covering solid and liquid tumors.
This OncoPoll™ focuses on the continued evolution of targeted therapy, and especially on the clinical impact of exciting new updates for Immune Checkpoint Inhibitors. Our most recent research from 125 global oncologists managing NSCLC patients uncovers that:
- For cases of NSCLC without driver mutations, treatment with the anti-PD-1/PD-L1 antibodies is expected to become the main 2nd line treatment option
- These anti-PD-1/PD-L1 antibodies WILL be included in the treatment of ALK+ or EGFR-mutated NSCLC, albeit in 1 later line of therapy (primarily starting in 3rd line)
- Combining the anti-PD-1/PD-L1 antibodies with the anti-CTLA-4 antibody ipilimumab is seen as a promising approach that will further impact treatment paradigms in the future
- Even at today’s prices, physicians see good value in using the anti-PD-1/PD-L1 antibodies for NSCLC
Download your complimentary copy of the MDoutlook 2015 ASCO Syndicated NSCLC OncoPoll through the link.
MDoutlook continues its commitment to the cancer community to provide meaningful, timely and relevant insight. As in previous years, we work with Oncology Business Review to share this important research widely.
MDoutlook is disease intelligence redefined. Governed by top ThoughtLeaders and driven by in-house MD and PhD medical experts, MDoutlook® is powered by a proprietary, global cloud-based disease intelligence platform accessing 1M+ multi-disciplinary treaters of complex diseases, including cancer, hematology, auto-immune diseases.
Email or phone (+1.404.496.4136 / 888.3outlook) to discuss how MDoutlook can answer your disease intelligence needs.